drugset
drugset / Trial / NCT07431112

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

NCT07431112 ↗

Phase 1 Recruiting 54 enrolled AIRNA Corporation
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.

Timeline

Start
2026-03-17
Primary completion
2028-11
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AIR001 Oligonucleotide (other) — Subcutaneous

Indications

alpha 1-antitrypsin deficiency